Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine in Japanese patients with advanced solid tumors
NCT03324113Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2017
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tusamitamab ravtansine in solid tumor, sponsored by Sanofi. Primary endpoint: IMP-related dose limiting toxicities at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
tusamitamab ravtansine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03324113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324113.